Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: A prospective study

International Journal of Cancer

Volumn 125, Issue 5, 2009, Pages 1143-1146

  Mucci, Lorelei A ^a,b   Stark, Jennifer R ^a,b   Figg, William D ^c   Schumacher, Fredrick ^a,b,d   Li, Haojie ^a   Abe, Miyako ^e   Hennessy, Kristen ^e   Stampfer, Meir J ^a,b   Gaziano, John Michael ^a,f   Ma, Jing ^a   Kantoff, Philip W ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Endostatin; Obesity; Prostate cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOSTATIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BODY MASS; CANCER RISK; CANCER SURVIVAL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NEOVASCULARIZATION (PATHOLOGY); OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; BODY MASS INDEX; CASE-CONTROL STUDIES; ENDOSTATINS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; OVERWEIGHT; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 67650045692     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24423     Document Type: Article

References (22)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Folkman J. Angiogenesis. Cancer: Principles and Practice of Oncology. In: DeVita V, Hellman S, Rosenberg S, eds. Philadelphia: Lippincott, 1997:3075-85.
4. van Moorselaar RJ, Voest EE. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol 2002;197:239-50.
5. Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940-4.
6. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1997;79:772-9.
7. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999;274:11721-6.
8. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
9. Iughetti P, Suzuki O, Godoi PH, Alves VA, Sertie AL, Zorick T, Soares F, Camargo A, Moreira ES, di Loreto C, Moreira-Filho CA, Simpson A, et al. A polymorphism in endostatin, an angiogenesis inhibitor, predisposes for the development of prostatic adenocarcinoma. Cancer Res 2001;61:7375-8.
10. Menzel O, Bekkeheien RC, Reymond A, Fukai N, Boye E, Kosztolanyi G, Aftimos S, Deutsch S, Scott HS, Olsen BR, Antonarakis SE, Guipponi M. Knobloch syndrome: novel mutations in COL18A1, evidence for genetic heterogeneity, and a functionally impaired polymorphism in endostatin. Hum Mutat 2004;23:77-84.
11. Rupnick MA, Panigrahy D, Zhang CY, Dallabrida SM, Lowell BB, Langer R, Folkman MJ. Adipose tissue mass can be regulated through the vasculature. Proc Natl Acad Sci USA 2002;99:10730-5.
12. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003;95:1240-4.
13. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001;10:345-53.
14. Henneckens CH, Buring JE, Manson JE, Stampfer MJ, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with β-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
15. Macpherson GR, Singh AS, Bennett CL, Venzon DJ, Liewehr DJ, Franks ME, Dahut WL, Kantoff PW, Price DK, Figg WD. Genotyping and functional analysis of the D104N variant of human endostatin. Cancer Biol Ther 2004;3:1298-303.
16. Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Gaziano JM, Pollak M, Stampfer MJ. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 2008;9:1039-47.
17. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18.
18. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51.
19. Fukai N, Eklund L, Marneros AG, Oh SP, Keene DR, Tamarkin L, Niemela M, Ilves M, Li E, Pihlajaniemi T, Olsen BR. Lack of collagen XVIII/endostatin results in eye abnormalities. Embo J 2002;21: 1535-44.
20. Li HC, Cai QY, Shinohara ET, Cai H, Cao C, Wang ZF, Teng M, Zheng W, Lu B. Endostatin polymorphism 4349G/A(D104N) is not associated with aggressiveness of disease in prostate [corrected] cancer. Dis Markers 2005;21:37-41.
21. Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprini D, Chu W, Ho M, Sweet J, Evans A, Toi A, Pollak M, et al. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1429-37.
22. Silha JV, Krsek M, Sucharda P, Murphy LJ. Angiogenic factors are elevated in overweight and obese individuals. Int J Obes (Lond) 2005;29:1308-14.